<PAGE> 1
===============================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A-1
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended December 31, 1998
or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 1-12574
TEXAS BIOTECHNOLOGY CORPORATION
(Exact name of Registrant as specified in its charter)
Delaware 13-3532643
(State of Incorporation) (I.R.S. Employer
Identification Number)
7000 Fannin, Suite 1920
Houston, Texas 77030
(713) 796-8822
(Address and telephone number of principal executive offices and zip code)
================================================================================
<PAGE> 2
ITEM 14(b). REPORTS ON FORM 8-K.
One report on Form 8-K was filed on December 16, 1998 regarding the
amendment of the NDA for NOVASTAN(R).
<PAGE> 3
SIGNATURES
PURSUANT TO THE REQUIREMENTS OF SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON
ITS BEHALF BY THE UNDERSIGNED, THEREUNTO DULY AUTHORIZED, IN THE CITY OF HOUSTON
AND STATE OF TEXAS ON THE 31ST DAY OF MARCH, 1999.
TEXAS BIOTECHNOLOGY CORPORATION
By: /s/ STEPHEN L. MUELLER
----------------------------------
Stephen L. Mueller
Vice President, Finance and Administration
Secretary and Treasurer
